Taysha Gene Therapies (NASDAQ:TSHA – Get Free Report) had its price target reduced by Canaccord Genuity Group from $7.00 to $6.00 in a report released on Wednesday, Benzinga reports. The firm presently has a “buy” rating on the stock. Canaccord Genuity Group’s price objective would suggest a potential upside of 91.69% from the company’s previous […]
Taysha Gene Therapies (NASDAQ:TSHA – Get Free Report) and ProKidney (NASDAQ:PROK – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, dividends, earnings, institutional ownership and profitability. Valuation and Earnings This table compares Taysha […]
Protara Therapeutics (NASDAQ:TARA – Get Free Report) and Taysha Gene Therapies (NASDAQ:TSHA – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, valuation, profitability, analyst recommendations, institutional ownership and dividends. Profitability This table compares Protara Therapeutics […]
Taysha Gene Therapies (NASDAQ:TSHA – Free Report) had its price objective increased by Truist Financial from $2.00 to $6.00 in a research note published on Tuesday morning, Marketbeat Ratings reports. Truist Financial currently has a buy rating on the stock. A number of other brokerages have also recently commented on TSHA. Robert W. Baird raised […]